AIOSYN
Aiosyn, a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform. By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of Chronic Kidney Disease (CKD) therapies using new and quantitative insights offered through Nephropath’s Kidney Image Analysis Services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228760007/en/
Figure 1. Illustration of the NephroPath platform’s capabilities in performing automated quantification and multi-class prediction on an entire rat kidney cortex. Notable classes: normal tubuli (orange), atrophic/dilated tubuli (green/red), glomeruli (pink), abnormal/sclerotic glomeruli (dark blue), arteries (light blue), interstitium (not colored). (Photo: Business Wire)
The NephroPath platform provides computational pathology algorithms for a detailed evaluation of histological biomarkers in kidney biopsies, including segmentation of main tissue classes, quantification of interstitial fibrosis, precise localization and quantification of glomeruli, and more. These AI-powered analyses effectively overcome the constraints of current semi-quantitative scoring systems, which are often based on subregions of the kidney and are subject to observer variability.
NephroPath’s AI-based quantification provides reproducible, consistent, fast, and more detailed scoring of renal pathology (imaging) biomarkers in preclinical and clinical specimens* compared to human reading. This can accelerate preclinical and clinical development projects. The algorithms will also be instrumental in new CKD biomarker discovery projects.
Through Nephropath’s Kidney Image Analysis Services, Aiosyn offers whole kidney quantification and custom kidney analyses. Aiosyn’s data-rich analysis derived from slide data provides per-slide tissue quantifications and detailed dataset characterization. Findings are delivered in a comprehensive image analysis report, including biomarker scores and visual results.
“Using Aiosyn's NephroPath platform we provide researchers with a new and powerful technique to complement the CKD drug development toolbox,” said Patrick de Boer, CEO of Aiosyn.
CKD is forecasted to grow to the fifth predominant cause of mortality by 2040 (1), and with over 90+ new CKD therapies in development, there is a need for advanced tools that can accelerate drug development and enhance diagnostic accuracy.
In a recent preclinical study, conducted in collaboration with a leading preclinical research organization (CRO), the NephroPath platform demonstrated its effectiveness in segmenting kidney tissue classes (Figure 1) and quantifying glomerulosclerosis and tubular damage on whole rat kidneys. A positive correlation was observed between the glomerulosclerosis and tubular scores and kidney damage across all groups (the study abstract will be presented at the upcoming CKD Summit in Boston from March 19-21).
To learn more about the NephroPath platform and to explore potential collaboration, request a demo with our team.
About Aiosyn
Aiosyn is a Dutch company that develops precision pathology software for cancer and kidney disease. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon more than 20 years of research experience in the field of pathology and is rooted in the pathology practice.
*For scientific validity only. The NephroPath platform is for Research Use Only and should not be used for diagnostic procedures.
Sources
- Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, M., … & Murray, C. J. (2018). Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. The Lancet, 392(10159), 2052-2090.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228760007/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom